JENA, Germany, Sept. 26, 2011 /CNW/ - Occlutech, a leading European
developer of implants for treating structural heart disease today
announced that its CEO, Mr Tor Peters, has obtained a favorable ruling
from the district court in Duesseldorf in patent litigation initiated
personally against him by St Jude AGA Medical.
On the 10th of May 2011, Occlutech GmbH won an over 5 years long patent
lawsuit initiated by St Jude-AGA Medical at the German Supreme Court in
Karlsruhe regarding infringement of patent EP 808 138.
In further proceedings at the Regional Court in Duesseldorf, St Jude-AGA
Medical accused the CEO of Occlutech GmbH, Mr Tor Peters, privately for
alleged violation of patent EP 808 138. In a ruling dated September 8th
2011, this claim has now also been rejected by the District Court in
Duesseldorf. The ruling is subject to appeal by St Jude-AGA Medical.
Tor Peters says; "It is amazing and quite shocking to see a company that
you would normally consider ethical, going to such length in trying to
kill a competitor by also going after private individuals with this
kind of massive and unjustified litigation. Obviously we are very happy
that the courts in Germany now ruled in our favor as courts in The UK,
The Netherlands and Sweden have done before."
Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities such as Atrial Septal
Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel
between the heart's two atria, present in up to 25% of the population),
in minimally invasive, non-surgical procedures. The market for PFO
occluders is expected to expand significantly as the link between PFO
and stroke, that is the third most common cause of death, as well as
severe migraine becomes increasingly well documented.
SOURCE Occlutech GmbH
For further information:
Katrin Biedermann, +49-3641-67-51-20, email@example.com; Tor Peters , +49-3641-67-51-29, firstname.lastname@example.org